Not All GLP-1s Are Equal—Here’s What Actually Matters
Everyone is celebrating this news about telehealth expanding access to Wegovy (semaglutide):
Novo Nordisk has partnered with major telehealth platforms to make FDA-approved Wegovy more accessible, with direct-to-patient delivery and simplified prescribing pathways.
On the surface, this looks like a win:
Greater access. Lower friction. More patients treated.
But here’s the part almost nobody is talking about.
Semaglutide is not the best drug in this class anymore.
In clinical studies, roughly 40–50% of the weight lost with semaglutide can come from lean mass—muscle, bone, and other metabolically important tissue.
That matters because muscle and bone preservation are among the strongest predictors of longevity and healthspan.
Weight loss alone is not longevity medicine.
Meanwhile, tirzepatide (a dual-incretin drug) consistently produces greater weight loss in trials and appears to preserve body composition more favorably.
And the next-generation drug — retatrutide — may be even more powerful.
Yet patients are being marketed “$99 GLP-1s” through telehealth ads.
Those prices almost always reflect the starter titration dose, not the therapeutic dose most patients ultimately need.
By the time patients reach effective dosing, the real monthly cost often ends up in the $250–$400 range regardless of which drug you choose.
So choosing a medication based on the introductory price is often the wrong question.
The right question is:
Which therapy improves metabolic health while preserving muscle and long-term function?
GLP-1 medications are extraordinary tools. They improve A1c, blood pressure, lipid profiles, and overall cardiometabolic risk.
But if you’re serious about longevity and healthspan, the goal isn’t simply to lose weight.
The goal is to lose fat while preserving the muscle that keeps you strong, functional, and independent for decades.
That requires the right drug — and the right program around it.